PMID- 38291721
OWN - NLM
STAT- MEDLINE
DCOM- 20240226
LR  - 20240226
IS  - 1545-5017 (Electronic)
IS  - 1545-5009 (Linking)
VI  - 71
IP  - 4
DP  - 2024 Apr
TI  - Percutaneous biopsy for the diagnosis, risk stratification, and molecular 
      profiling of neuroblastoma: A single-center retrospective study.
PG  - e30887
LID - 10.1002/pbc.30887 [doi]
AB  - PURPOSE: To determine whether percutaneous core needle biopsy (PCNB) is adequate 
      for the diagnosis and full molecular characterization of newly diagnosed 
      neuroblastoma. MATERIALS AND METHODS: Patients with newly diagnosed neuroblastoma 
      who underwent PCNB in interventional radiology at a single center over a 5-year 
      period were included. Pre-procedure imaging and procedure details were reviewed. 
      Rates of diagnostic success and sufficiency for International Neuroblastoma 
      Pathology Classification (INPC), risk stratification, and evaluation of genomic 
      markers utilized in the Children's Oncology Group risk stratification, and status 
      of the anaplastic lymphoma kinase (ALK) gene were assessed. RESULTS: Thirty-five 
      patients (13 females, median age 2.4 years [interquartile range, IQR: 0.9-4.4] 
      and median weight 12.4 kg [IQR: 9.6-18]) were included. Most had International 
      Neuroblastoma Risk Group Stage M disease (n = 22, 63%). Median longest axis of 
      tumor target was 8.8 cm [IQR: 6.1-12]. A 16-gauge biopsy instrument was most 
      often used (n = 20, 57%), with a median of 20 cores [IQR: 13-23] obtained. 
      Twenty-five specimens were assessed for adequacy, and 14 procedures utilized 
      contrast-enhanced ultrasound guidance. There were two post-procedure bleeds 
      (5.7%). Thirty-four of 35 procedures (97%) were sufficient for histopathologic 
      diagnosis and risk stratification, 94% (n = 32) were sufficient for INPC, and 85% 
      (n = 29) were sufficient for complete molecular characterization, including ALK 
      testing. Biologic information was otherwise obtained from bone marrow (4/34, 12%) 
      or surgery (1/34, 2.9%). The number of cores did not differ between patients with 
      sufficient versus insufficient biopsies. CONCLUSION: In this study, obtaining 
      multiple cores with PCNB resulted in a high rate of diagnosis and successful 
      molecular profiling for neuroblastoma.
CI  - (c) 2024 Wiley Periodicals LLC.
FAU - Schoeman, Sean
AU  - Schoeman S
AUID- ORCID: 0000-0002-6221-6929
AD  - Department of Radiology, Children's Hospital of Philadelphia (CHOP), 
      Philadelphia, Pennsylvania, USA.
FAU - Bagatell, Rochelle
AU  - Bagatell R
AUID- ORCID: 0000-0002-5729-8819
AD  - The Perelman School of Medicine, University of Pennsylvania, Philadelphia, 
      Pennsylvania, USA.
AD  - Department of Oncology, Children's Hospital of Philadelphia (CHOP), Philadelphia, 
      Pennsylvania, USA.
FAU - Cahill, Anne Marie
AU  - Cahill AM
AD  - Department of Radiology, Children's Hospital of Philadelphia (CHOP), 
      Philadelphia, Pennsylvania, USA.
AD  - The Perelman School of Medicine, University of Pennsylvania, Philadelphia, 
      Pennsylvania, USA.
FAU - Maris, John
AU  - Maris J
AUID- ORCID: 0000-0002-8088-7929
AD  - The Perelman School of Medicine, University of Pennsylvania, Philadelphia, 
      Pennsylvania, USA.
AD  - Department of Oncology, Children's Hospital of Philadelphia (CHOP), Philadelphia, 
      Pennsylvania, USA.
FAU - Mattei, Peter
AU  - Mattei P
AD  - The Perelman School of Medicine, University of Pennsylvania, Philadelphia, 
      Pennsylvania, USA.
AD  - Division of General, Thoracic and Fetal Surgery, Children's Hospital of 
      Philadelphia (CHOP), Philadelphia, Pennsylvania, USA.
FAU - Mosse, Yael
AU  - Mosse Y
AD  - The Perelman School of Medicine, University of Pennsylvania, Philadelphia, 
      Pennsylvania, USA.
AD  - Department of Oncology, Children's Hospital of Philadelphia (CHOP), Philadelphia, 
      Pennsylvania, USA.
FAU - Pogoriler, Jennifer
AU  - Pogoriler J
AD  - The Perelman School of Medicine, University of Pennsylvania, Philadelphia, 
      Pennsylvania, USA.
AD  - Division of Anatomical Pathology, Children's Hospital of Philadelphia (CHOP), 
      Philadelphia, Pennsylvania, USA.
FAU - Srinivasan, Abhay
AU  - Srinivasan A
AD  - Department of Radiology, Children's Hospital of Philadelphia (CHOP), 
      Philadelphia, Pennsylvania, USA.
AD  - The Perelman School of Medicine, University of Pennsylvania, Philadelphia, 
      Pennsylvania, USA.
FAU - Acord, Michael
AU  - Acord M
AD  - Department of Radiology, Children's Hospital of Philadelphia (CHOP), 
      Philadelphia, Pennsylvania, USA.
AD  - The Perelman School of Medicine, University of Pennsylvania, Philadelphia, 
      Pennsylvania, USA.
LA  - eng
PT  - Journal Article
DEP - 20240130
PL  - United States
TA  - Pediatr Blood Cancer
JT  - Pediatric blood & cancer
JID - 101186624
RN  - Q37G40S4S8 (quintozene)
RN  - EC 2.7.10.1 (Receptor Protein-Tyrosine Kinases)
RN  - 0 (Nitrobenzenes)
SB  - IM
MH  - Child
MH  - Female
MH  - Humans
MH  - Child, Preschool
MH  - Retrospective Studies
MH  - Biopsy/methods
MH  - Biopsy, Large-Core Needle
MH  - *Neuroblastoma/diagnosis/genetics/pathology
MH  - Risk Assessment
MH  - Receptor Protein-Tyrosine Kinases
MH  - Image-Guided Biopsy
MH  - *Nitrobenzenes
OTO - NOTNLM
OT  - image-guided
OT  - interventional radiology
OT  - neuroblastoma
OT  - percutaneous biopsy
EDAT- 2024/01/31 06:42
MHDA- 2024/02/26 06:44
CRDT- 2024/01/31 01:12
PHST- 2024/01/10 00:00 [revised]
PHST- 2023/10/06 00:00 [received]
PHST- 2024/01/11 00:00 [accepted]
PHST- 2024/02/26 06:44 [medline]
PHST- 2024/01/31 06:42 [pubmed]
PHST- 2024/01/31 01:12 [entrez]
AID - 10.1002/pbc.30887 [doi]
PST - ppublish
SO  - Pediatr Blood Cancer. 2024 Apr;71(4):e30887. doi: 10.1002/pbc.30887. Epub 2024 
      Jan 30.